Rewriting Diabetes Therapy: How Incretin Modulation is Transforming Cardiovascular and Renal Outcomes

Area of Science:

• Cardiology
• Nephrology
• Endocrinology
• Pharmacology

Background:

• Type 2 diabetes mellitus (T2DM) is a major driver of cardiovascular (CV) disease and chronic kidney disease (CKD), leading to increased morbidity and mortality.
• Incretin-based therapies offer potential cardiorenal protective benefits beyond glycemic control.

Purpose of the Study:

• To review the mechanistic pathways and clinical trial evidence for incretin-based therapies, focusing on cardiorenal outcomes.
• To assess the role of GLP-1 receptor agonists (GLP-1RA), DPP-4 inhibitors, and newer dual/triple agonists in managing cardiorenal risk in T2DM.

Main Methods:

• A narrative review of mechanistic studies and randomized controlled trials involving GLP-1 receptor agonists (GLP-1RA), DPP-4 inhibitors, and dual/triple agonists.
• Inclusion of recent pivotal trial data (SELECT, FLOW, SOUL, SURPASS-CVOT) and emerging oral small-molecule GLP-1R agonists.

Main Results:

• Long-acting GLP-1RA consistently reduce major adverse CV events (MACE), CV/all-cause death, heart failure hospitalizations, and kidney disease progression, irrespective of HbA1c levels.
• Semaglutide demonstrated CV risk reduction in obesity (SELECT) and kidney protection in T2DM with CKD (FLOW). Oral semaglutide reduced MACE in T2DM with ASCVD/CKD (SOUL).
• GLP-1R signaling mechanisms align with observed anti-inflammatory, natriuretic, and antifibrotic effects. Emerging oral agents show promise but lack long-term outcome data.

Conclusions:

• Incretin-based therapies have evolved to prioritize cardiorenal risk reduction over solely glucose-lowering targets in T2DM management.
• GLP-1RA are recommended for T2DM patients with high cardiorenal risk, regardless of HbA1c. Dual agonists and oral agents may expand indications pending further evidence.